Stray Dog

Barclays lifts HIMS target to $39 as shares clear $30

  • Good news: Barclays raised its target from $29 to $39 (Overweight), saying alt-data show an inflection since the Novo Nordisk partnership.
  • Good news: Shares closed at $31.47 on 17 Jun, above the $30-32 resistance zone that had capped them since April.
  • Mixed: Leerink stays at $25, and the rally is mainly technical repair and sentiment, not a new fundamental turning point.
Read the full notes

Sell-side views have split to an extreme (Leerink $25 vs Barclays $39), and Barclays is now the most aggressive bull among the analysts covering the stock. Its view: alt-data show a clear inflection since the Novo Nordisk partnership, and the weight-loss business will drive faster revenue growth in the second half.

Read more

On 17 Jun the shares moved above the key $30-32 resistance zone (which has repeatedly capped them since April), and the technical significance outweighs the day's gain. But this rally is mainly down to the alt-data inflection from the Novo partnership, a technical repair as resistance broke, and Barclays igniting sentiment. It is not a new fundamental turning point. The FDA advisory committee on peptide compounding on 23-24 Jul is still the core binary event.

Key evidence

  • Barclays research note, 16 Jun: target raised from $29 to $39 (Overweight maintained), implying about 21% upside and among the highest targets in coverage
  • Barclays's logic: alt-data show a clear inflection since the Novo Nordisk partnership. Weight loss and other modest contributors will together drive faster revenue growth in the second half, creating a chance of a 'breakout in the shares'.
  • In the same week Leerink reiterated Market Perform with a $25 target, the polar opposite of Barclays's $39
  • The core disagreement: the near-term earnings trajectory of GLP-1 versus a long-term re-rating of the platform and peptides
  • Closed at $31.47 on 17 Jun (+4.31%), touching $32.22 intraday, up about 13% over the week
  • $30-32 is the resistance zone that has repeatedly capped the shares since April. This time they broke above it and held.
Show 2 more
  • Above the 20-day ($26.60) and 50-day ($26.07) moving averages, but still well below the 52-week high of $70.43
  • FirstWave Fund CEO Jonah Lupton publicly estimates HIMS's annual peptide revenue potential at $10 billion to $19 billion (a personal view, not company guidance)

Catalysts to watch

  • FDA advisory committee meeting on peptide compounding, 23-24 Jul (the core binary event)
  • Continued confirmation from alt-data on the Novo Nordisk partnership
  • Visibility on revenue acceleration in the second half (Barclays's focus)

Risks

  • Lupton's estimate of $10 billion to $19 billion in peptide revenue assumes FDA PCAC clearance on 23-24 Jul. It is an upper-bound assumption for an optimistic scenario.
  • Even if the advisory committee votes in favour, the FDA still has the final say
  • This rally is not a new fundamental turning point. It is mainly technical repair plus a spark to sentiment.
  • Sell-side views have split to an extreme ($25 vs $39), so there is no consensus
  • Still well below the 52-week high of $70.43, and the path to a long-term re-rating is unconfirmed

Sources 5

  1. Barclays research note, 16 Jun
  2. Leerink reiteration of Market Perform
  3. Intraday price data, 17 Jun
  4. Public comments by FirstWave Fund CEO Jonah Lupton
  5. Alt-data on the Novo Nordisk partnership